New data on the pathogenesis of preeclampsia
https://doi.org/10.24884/1682-6655-2018-17-4-
Abstract
Currently, preeclampsia is one of the most significant problems in obstetrics and gynecology. The significance of this pathology is determined by its high prevalence and pathological impact on the organism of both mother and fetus. The pathogenesis of preeclampsia is very complex, involving many different interrelated, complementary pathophysiological and biochemical reactions. One of the main mechanisms of preeclampsia development is the excessive synthesis of antiangiogenic factors that, among other effects, contribute to increased activity of a number of substances with vasoconstrictor action. These changes lead to the formation of placental insufficiency and the development of clinically overt disease. Among the most important substances that contribute to the formation of excessive uncontrolled vasospasm are endogenous digitalis-like factors (EDFs) which regulate the activity of Na+/K+-ATPase. The most important structural class of EDFs is represented by bufadienolides. The classic representative of this group is marinobufagenin. It selectively blocks the α-1 isoform of Na+/K+-ATPase, widely represented in the renal tubules thereby having the properties of potent.
About the Author
V. A. Reznik
Federal State Budgetary Educational Institution of Higher Education «Saint-Petersburg State Pediatric Medical University» of Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
MD, PhD, Associate Professor, Department of Obstetrics and Gynecology,
194100, St. Petersburg, Litovskaya street, 2
References
1. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia Annu Rev Pathol. 2010;5:173–192. Doi: 10.1146/annurev-pathol-121808-102149.
2. Litwińska E, Litwińska M, Oszukowski Pet al. Combined screening for early and late pre-eclampsia and intrauterine growth restriction by maternal history, uterine artery Doppler, mean arterial pressure and biochemical markers. Adv Clin Exp Med. 2017; 26(3):439–448. Doi: 10.17219/acem/62214.
3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–137. Doi: 10.1053/j. semperi.2009.02.010.
4. Saleem S, McClure EM, Goudar SS et al. A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. Bull World Health Organ 2014;92:605– 612. Doi: http://dx.doi.org/10.2471/BLT.13.127464.
5. Say L, Chou D, Gemmill A et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014;2(6):e323–e333. Doi: 10.1016/S2214-109X(14) 70227-X.
6. Karumanchi SA, Lindheimer MD. Advances in Understanding of eclampsia. Curr Hypertens Rep. 2008;10(4):305–312.
7. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Lancet. 2010 21;376(9741):631–644. Doi: 10.1016/S0140- 6736(10)60279-6.
8. Magee LA, Pels A, Helewa M et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive. J Obstet Gynaecol Can. 2014;36(7):575– 576. Doi: 10.1016/S1701-2163(15)30533-8.
9. Browne JL, Vissers KM, Antwi E et al. Perinatal outcomes after hypertensive disorders in pregnancy in a low resource setting. Trop Med Int Health. 2015;20(12):1778–11786. Doi: 10.1111/tmi.12606.
10. Davis EF, Lewandowski AJ, Aye C et al. Clinical cardiovascular risk during young adulthood in offspring of hypertensive pregnancies: insights from a 20-year prospective follow-up birth cohort. BMJ Open. 2015;5(6):e008136. Doi: 10.1136/bmjopen-2015-008136.
11. Herzog EM, Eggink AJ, Willemsen SP et al. Early- and late-onset preeclampsia and the tissue-specific epigenome of the placenta andnewborn. Placenta. 2017;58:122–132. Doi: 10.1016/j.placenta.2017.08.070.
12. Boafor TK, Olayemi E, Galadanci N et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2016;123(5):691–698. Doi: 10.1111/1471-0528.13786.
13. White WM, Mielke MM, Araoz PA et al. A history of preeclampsia is associated with a risk for coronary artery calcification 3 decades later. Am J Obstet Gynecol. 2016;214(4):519. e1-519.e8. doi: 10.1016/j.ajog.2016.02.003.
14. Fields JA, Garovic VD, Mielke MM et al. Preeclampsia and cognitive impairment later in life. Am J Obstet Gynecol.2017;217(1):74.e1–74.e11. Doi: 10.1016/j.ajog.2017. 03.008.
15. Bhargava S, Tyagi SC. Nutriepigenetic regulation by folate-homocysteine-methionine axis: a review. Mol Cell Biochem. 2014;387(1-2):55–61. Doi: 10.1007/s11010-013-1869-2.
16. Nadeau-Vallée M, Obari D, Palacios J, et al. Sterile inflammation and pregnancy complications: a review Reproduction. Reproduction. 2016;152(6):R277–R292. Doi:10.1530/ REP-16-0453.
17. Bokslag A, van Weissenbruch M., Mol BW, de Groot CJ. Preeclampsia: short and long-term consequences for mother and Early Hum Dev. 2016;102:47–50. Doi: 10.1016/j.earlhumdev.2016.09.007.
18. Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: involvement of oxidative stress and implications in human evolution. Hum Reprod Update. 2006; 12(6):747–755. Doi: 10.1093/humupd/dml016.
19. Krasnyi FV, Kan NE, Tyutyunnik VL et al. Oxidative stress in preeclampsia and in normal pregnancy. The Journal Obstetrics and Gynecology. 2016;5:90–94. Doi: 10.18565/aig.2016.5.90-94. (In Russ.).
20. Draganovic D, Lucic N, Jojic D. Oxidative Stress Marker and Pregnancy Induced Hypertension. Med Arch. 2016;70(6):437–440. Doi: 10.5455/medarh.2016.70. 437- 440. DOI: 10.5455/medarh.2016.70.437-440.
21. Gaziyeva IA, Chistyakova GN Markers of dysregulation of angiogenesis in the threatened miscarriage in the first trimester. Medical Immunology. 2007; 9(2–3):256. (In Russ.).
22. Kudryashova V, Sotnikova NYu, Panova I.A, Kadyrova LV. Differentiation of memory cells in the population of T-helpers in uncomplicated pregnancy and preeclampsia. Journal of obstetrics and women’s diseases. 2013; LXII (2):110–116. (In Russ.).
23. Chatterjee P, Chiasson VL, Seerangan G et al. Depletion of MHC class II invariant chain peptide or γ-δ T-cells ameliorates experimental. Clin Sci (Lond). 2017;131(15):2047– 2058. Doi: 10.1042/CS20171008.
24. Abdullaeva NK. Rossiyskiy vestnik akusheraginekologa. 2014;5:18–21. (In Russ.).
25. Darmochwal-Kolarz DA, Kludka-Sternik M, Chmielewski T et al. The expressions of CD200 and CD200R molecules on myeloid and lymphoid dendritic cells inpre-eclampsia and normal pregnancy. Am J Reprod Immunol. 2012;67(6):474– 481. Doi: 10.1111/j.1600-0897.2012.01126.x.
26. Glukhova TN, Chesnokova NP, Rogozhina IE, Sergeeva ON. Modern understanding of the pathogenesis of preeclampsia as a set of sample pathological process and pathological conditions, complicated pregnancy. Medical Sciences. 2016;2:12– 32. (In Russ.).
27. Naljayan MV, Karumanchi SA. New Developments in the Pathogenesis of Preeclampsia. Adv Chronic Kidney Dis. 2013;20(3):265–270. Doi: 10.1053/j.ackd.2013.02.003.
28. Seki H. Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. Acta Obstet Gynecol Scand. 2014;93(10):959–964. Doi: 10.1111/ aogs.12473.
29. Sokolov DI, Kolobov AV, Lesnichija MV, Kostiouchek IN, et al. Role of pro- and antiangiogenic fac tors in placental development. Medical Immunology. 2008; 10(4–5):347–352. (In Russ.).
30. Khodjaeva ZS, Musienko EV, Sukhykh GT. Problems of reproduction. 2011;2:30–34. (In Russ.).
31. Yakovleva NY, Khazova EI, Vasil’eva EY, Zazerskaya IE. Ratio of angiogenic and anti-angiogenic factors in preeclampsia. «Arterial’naya Gipertenziya» («Arterial Hypertension»). 2016;22(5):488–494. Doi:10.18705/1607-419X-2016-22-5-488-494. (In Russ.).
32. Ul’yanina EV, Fatkullin IF. Vascular endothelial growth factor role in predicting vascular disorders in pregnant with fetal growth restriction syndrome. Kazan medical journal. 2015;96(2):220–223. Doi: dx.doi.org/10.17750/KMJ2015- 220. (In Russ.).
33. Eremina V, Sood M, Haigh J et al. Glomerularsspecific alterations of VEGF-A expression lead to distinct congenital and acquired renal. J Clin Invest. 2003;111(5):707–716. Doi: 10.1172/JCI17423.
34. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005. Doi:10.1056/ NEJMoa055352.
35. Volkova EV, Lysiuk EYu, Djohadze LS. The role of pro- and antiangiogenic growth factors in the determination of preeclampsia severity degree bulletin of the Ivanovo Medical Academy. 2013;18(3):50–53. (In Russ.).
36. Jin ZG, Wong C, Wu J, Berk BC. Flow shear stress stimulates Gab1 tyrosine phosphorylation to mediate protein kinase B and endothelial nitric-oxide synthase activation in endothelial cells. J Biol Chem. 2005;280(13):12305–9. Doi: 10.1074/jbc.M500294200.
37. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J Pregnancy. 2012;2012:586578. Doi: 10.1155/2012/586578.
38. Lingrel JB, Kuntzweiler T. Na+,K+-ATPase. J Biol Chem. 1994;269(31):19659–62.
39. Beguin P, Wang X, Firsov D et al. The gamma-subunit is a specific component of the Na/K-ATPase and modulates its transport function. EMBO J. 1997;16(14):4250–4260.
40. Blanco G, Mercer RW. Isozymes of the Na/K-ATPase: heterogeneity in structure, diversity in finction. Am J Physiol. 1998;275(5 Pt 2):F633–50.
41. Glushakov RI, Proshin SN, Tapilskaya NI. The role of thyroid hormones in the regulation of angiogenesis, cell proliferation and migration. Genes and cells. 2011;6(4):26–33. (In Russ.).
42. Averina IV, Tapilskaya NI, Reznik VA, et al. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell Mol Biol (Noisy-le-grand). 2006;52(8):19–23.
43. Nikitina ER,Mikhailov AV,Nikandrova ES et al. In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical. J Hypertens. 2011;29(4):769–776. Doi: 10.1097/HJH. 0b013e32834436a7.
44. Fedorova OV, Lakatta EG, Bagrov AY. Differential effects of acute NaCl loading on endogenous ouabain like and marinobufagenin like ligands of the sodium pump in Dahl hypertensive rats. Circulation. 2000;102:3009–3014.
45. Morton JS, Cooke CL, Davidge ST. In Utero Origins of Hypertension: Mechanisms and Targets for Therapy. Physiol Rev. 2016;96(2):549–603. Doi: 10.1152/physrev.00015.2015.
46. Flier JS, Edwards MW, Daly JW, Myers CW. Widespread occurrence in frogs and toads of skin compounds interacting with the ouabain site of Na+/K+-ATPase. Science. 1980;208(4443):503–505.
47. Periyasamy SM, Liu J, Tanta F et al. Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney Int. 2005;67(5):1868-77. Doi: 10.1111/j.1523-1755.2005.00285.x.
48. Gonick HC, Ding Y, Vaziri ND et al. Simultaneous measurement of marinobufagenin, ouabain and hypertension associated protein in various disease states. Clin Exp Hypertens. 1998;20(5–6):617–627.
49. Fedorova OV, Bagrov AY. Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different alphasubunit isoforms. Am J Hypertens. 1997;10(8):929–935.
50. Lopatin DA, Ailamazian EK, Dmitrieva RI et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens. 1999;17(8):1179–1187.
51. Bagrov AY, Agalakova NI, Kashkin VA, Fedorova OV. Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats. Am J Hypertens. 2009;22(5):559–563. Doi: 10.1038/ajh.2009.22.
52. Fedorova OV, Zhuravin IA, Agalakova NI, et al. Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor J Hypertens. 2007;25(9):1834–1844. Doi:10.1097/HJH.0b013e328200497a.
53. Leenen FHH. Ruzicka M, Huang BS. The brain and saltsensitive hypertension. Curr Hypertens Rep. 2002;4(2):129–135.
54. Fedorova OV, Agalakova NI, Talan MI et al. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl loaded Dahl-S rats. J Hypertens. 2005;23(8):1515–1523.
55. Fedorova OV, Simbirtsev AS, Kolodkin NI et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens. 2008;26(12):2414–2425. Doi: 10.1097/ HJH.0b013e328312c86a.
56. Fedorova OV, Zernetkina VZ, Shilova VY, et al. Synthesis of an endogenous steroidal Na pump- inhibitor marinobufagenin, implicated in human cardiovascular diseases, is initiated by CYP27A1 via bile acid pathway. Circ Cardiovasc Genet. 2015;8(5):736–745. Doi: 10.1161/CIRCGENETICS.115.001217.
57. Hopoate-Sitake ML, Adair CD, Mason LA et al. Digibind reverses inhibition of cellular rb+ uptake caused by endogenous sodium pump inhibitors present in serum and placenta of women with preeclampsia. Reprod Sci. 2011;18(2):190–199. Doi: 10.1177/1933719110385133.
58. Ma J, Esplin MS, Adair CD et al. Increasing evidence for and regulation of a human placental endogenous digitalis-like factor. Reprod Sci. 2012;19(4):437–448. Doi: 10.1177/1933719111424441.
59. Nikitina ER, Mikhailov AV, Nikandrova ES, et al. In preeclampsia, endogenous cardiotonic steroids induce vas cular fibrosis and impair vasorelaxation of umbilical arteries. J Hypertens. 2011;29(4):769–776. Doi: 10.1097/HJH. 0b013e32834436a7.
60. Yakovleva1 VV, Solodovnikova1 NG, Frolova EV et al. Ratio of angiogenic and anti-angiogenic factors in preeclampsia. «Arterial’naya Gipertenziya» («Arterial Hypertension»). 2011;29(4):391–396. URL: https://doi.org/10.18705/1607-419X-2016-22-5-488-494. Doi. org/10.18705/1607-419X-2011-17-4. (In Russ.).
Review
For citations:
Reznik V.A. New data on the pathogenesis of preeclampsia. Regional blood circulation and microcirculation. 2018;17(4):4-10. (In Russ.) https://doi.org/10.24884/1682-6655-2018-17-4-
Views:
1170
Email this article 
